cabergoline

Subscribe to Selected New Research on cabergoline

342 relevant articles (75 outcomes, 66 trials/studies) found for this Drug

Description: also acts as prolactin antagonist

Also Known As:

1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; Cabaser; Cabaseril; Dostinex; FCE 21336; FCE-21336; Galastop; Kenfarma brand of cabergoline; Paladin brand of cabergoline; Pharmacia brand of cabergoline; cabergoline diphosphate

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 23

Heterocyclic Compounds with 4 or More Rings

Ergolines: 73

cabergoline: 342

Experts

1.	Colao, Annamaria: 7 articles (10/2008 - 03/2003)
2.	Lombardi, Gaetano: 6 articles (10/2008 - 03/2003)
3.	Pivonello, Rosario: 5 articles (10/2008 - 03/2003)
4.	Di Sarno, A: 5 articles (11/2001 - 04/2000)
5.	Colao, A: 5 articles (11/2001 - 04/2000)
6.	Cappabianca, Paolo: 4 articles (04/2004 - 03/2003)
7.	Lombardi, G: 4 articles (11/2001 - 04/2000)
8.	Di Sarno, Antonella: 3 articles (10/2008 - 11/2003)
9.	Oertel, W H: 3 articles (09/2006 - 05/2000)
10.	Lissoni, P: 3 articles (11/2004 - 01/2003)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 06/01/1996 - "The 13 patients randomized to cabergoline and completing the study had significantly improved Unified Parkinson's Disease Rating Scale (UPDRS) motor scores and timed hand-tapping test scores" 11/01/1996 - "Our results indicate that the long-lasting effects of cabergoline could be beneficial for treating Parkinson's disease." 03/01/1993 - "Unified Parkinson's Disease Rating Scale scores, Hoehn and Yahr stage of disease, and computerized measures of motor performance improved significantly with cabergoline treatment" 09/13/2002 - "While cabergoline is commonly used to treat the motor dysfunction of Parkinson's disease, it may also be effective in inhibiting oxidative stress, a possible mechanism of dopaminergic neuronal degeneration in Parkinson's disease." 01/01/2001 - "Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease." Get all the results and reference details, order at left...
2.	Prolactinoma (Prolactinomas) 04/01/2004 - "These data demonstrate that cabergoline treatment is as effective and safe in men as in women with prolactinoma and can be successfully used as primary therapy even in men bearing large macroprolactinomas." 04/01/1997 - "CONCLUSIONS: Although the present data were not obtained in a formal study we conclude that cabergoline is an effective and well-tolerated treatment for macroprolactinoma patients." 02/01/2007 - "CONCLUSION: Cabergoline therapy appears to be effective and safe in men with giant prolactinomas" 04/01/1997 - "OBJECTIVE: Cabergoline is now established as an effective and well-tolerated treatment for prolactinoma" 08/01/1997 - "Cabergoline may be a useful treatment for aggressively growing non-prolactin-secreting pituitary adenomas." Get all the results and reference details, order at left...
3.	Neoplasms (Cancer) 01/01/2008 - "Cabergoline normalized serum PRL level, shrank the tumor mass remarkably, and caused marked improvement of visual acuity" 06/01/1996 - "During two further years of follow up, the improvement in PRL levels, gonadal function, and tumor size has persisted during cabergoline administration, and three patients have experienced a further decline in PRL and/or tumor size" 07/01/1999 - "The aim of this study was to examine, in a very large number of hyperprolactinemic patients, the ability to normalize PRL levels with cabergoline, to determine the effective dose and tolerance, and to assess the effect on clinical symptoms, tumor shrinkage, and visual field abnormalities" 07/01/2007 - "By 6 months after the patients began to take cabergoline, tumor shrinkage of 94% (in case 1) and of 70% (in case 2) was demonstrated by magnetic resonance imaging" 12/06/2006 - "Medical treatment with cabergoline led to a rapid regression of ophthalmologic symptoms and, subsequently, of tumor size" Get all the results and reference details, order at left...
4.	Hyperprolactinemia 01/01/2005 - "In conclusion, the excellent therapeutic efficacy and the lack of adverse events with Cabergoline promotes its use as a first line therapy of hyperprolactinemia due to pituitary microadenoma." 03/01/1997 - "Cabergoline (CAB), a new, potent, and long-lasting PRL-lowering agent, was shown to be effective in tumoral hyperprolactinemia" 06/01/1989 - "We conclude that cabergoline is effective treatment for hyperprolactinemia" 02/01/1996 - "CONCLUSIONS: Vaginal cabergoline is a safe and effective method of therapy for hyperprolactinemia and it avoids the adverse events of oral administration." 07/01/1999 - "Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients." Get all the results and reference details, order at left...
5.	Dyskinesias (Dyskinesia) 07/01/1999 - "Chronic cabergoline administration improved motor response with no persistent dyskinesia" 07/01/2000 - "During cabergoline treatment, the monkeys initially showed marked dyskinesias, which were reduced significantly after 4 weeks of treatment" 02/01/1996 - "In contrast, administration of the long-acting D2-like agonist cabergoline, which alleviated Parkinsonian symptoms without producing dyskinesia reduced deltaFosB levels to near normal" 01/01/1996 - "Cabergoline alone at 0.2 mg/kg or less improved in a dose-dependent fashion the parkinsonism without inducing hyperactivity and dyskinesia following a single subcutaneous injection" 09/01/1996 - "We conducted an open study to investigate the effectiveness and tolerability of cabergoline, administered once a day orally, in 50 consecutive patients with Parkinson's disease complicated by motor fluctuations and dyskinesias" Get all the results and reference details, order at left...
113 Diseases and 342 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Dopamine Agonists (Dopamine Agonist)
2.	Levodopa (L Dopa)
3.	Prolactin
4.	Bromocriptine (Parlodel)
5.	Pergolide (Permax)
6.	Risperidone (Risperdal Consta)
7.	Octreotide (Sandostatin)
8.	pramipexol (pramipexole)
9.	ropinirole (Requip)
10.	Carbon Monoxide
114 Drugs and Important Bio-Agents and 252 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Activities of Daily Living (ADL)
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)
4.	Transplantation (Transplant Recipients)
5.	Decompression
6 Therapies and Procedures and 9 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>